We’ve been asked several times about our New Year’s resolution(s).
Our response?
Revolution.
Our 2024 resolution is revolution. Revolution through evolution.
The revolution is to be carried out against the current despotic regime of widespread toxicity that characterizes how most diseases are treated.
In its place we propose the next generation of therapies that not only target diseases but also protect patients.
The main perpetrators of said revolution?
From our perspective it is the lead EpicentRx therapies, RRx-001 and AdAPT-001. As a reminder, RRx-001 is in a Phase 3 trial for 3rd line or beyond small cell lung cancer (SCLC). It will also start new clinical trials in 2024, a Phase 1 for the treatment of endometriosis and a Phase 2b for mitigation of severe oral mucositis, a common complication of chemoradiation therapy in first line head and neck cancer.
Also, AdAPT-001 is in an ongoing combination Phase 2 clinical trial for the treatment of resistant solid tumors mostly sarcomas, where it has demonstrated synergy with immune checkpoint inhibitors and—so far at least—no dose limiting toxicities.
The term revolution evokes corrupt backroom plots to grab power from a current democratic regime and its indefinite replacement with a dictatorship. However, this specific revolution is fully democratic not autocratic—it involves all patients, rather than just a select few, regardless of race, gender, class, skin color, religion, sexuality, or nationality who so desperately want and need freedom from diseases and from treatment-related toxicities.
So, welcome to the revolution. Welcome to the fight.
The revolution will be liked, Google’ed, tweeted, retweeted, posted, shared, televised, and, of course, blogged—right here.